Evidence map›Paper›PMID 40983528›Full record

ArticleBritish journal of haematology2025

Allogeneic haematopoietic cell transplantation in advanced systemic mastocytosis in the new era: A CIBMTR study.

Celalettin Ustun, Mei-Jie Zhang, Andrew Peterson, Alexander Baek, Mounzer Agha, Hassan Alkhateeb, Saurabh Chhabra, Alex Coltoff, Marcos de Lima, Arpita Gandhi and 24 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of haematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

34 authors.

Celalettin UstunDivision of Hematology/Oncology/Cell Therapy, Department of Medicine, Rush University, Chicago, Illinois, USA.ORCID https://orcid.org/0000-0001-6896-6213
Mei-Jie ZhangCIBMTR® (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Andrew PetersonCIBMTR® (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Alexander BaekCIBMTR® (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Mounzer AghaUPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
Hassan AlkhateebDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.ORCID https://orcid.org/0000-0002-3609-8404
Saurabh ChhabraDivision of Hematology/Oncology, Department of Medicine, Mayo Clinic, Phoenix, Arizona, USA.
Alex ColtoffDivision of Hematology/Oncology, Department of Medicine, MUSC, Charleston, South Carolina, USA.
Marcos de LimaThe James Comprehensive Cancer Center, Division of Hematology, The Ohio State University, Columbus, Ohio, USA.
Arpita GandhiKnight Cancer Institute, Oregon Health & Science University, Oregon, Portland, USA.
Vincent HoDivision of Hematologic Malignancies, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.
Adetola KassimDivision of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Adam LinDivision of Hematology/Oncology, Department of Medicine, Northwestern Memorial Hospital, Chicago, Illinois, USA.
Lohith GowdaHematology and Bone Marrow Transplantation, Yale University School of Medicine, New Haven, Connecticut, USA.
Gautam BorthakurDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0001-7679-6453
Daniel J DeAngeloDivision of Leukemia, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Joseph McGuirkDivision of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, USA.
Felix MensahHematology and Medical Oncology, Hematology, Medical Oncology, Fransciscan Health, Mishawaka, Indiana, USA.
Kalyan V NadimintiCarbone Cancer Center, Division of Hematology, Medical Oncology and Palliative Care, University of Wisconsin, Madison, Wisconsin, USA.ORCID https://orcid.org/0000-0001-9625-1178
Taiga NishihoriDepartment of Blood & Marrow Transplant and Cellular Immunotherapy (BMT CI), Moffitt Cancer Center, Tampa, Florida, USA.ORCID https://orcid.org/0000-0002-2621-7924
Jeremy PantinThe Sarah Cannon Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, Nashville, Tennessee, USA.
Andrew TrunkThe University of Utah Transplant and Cellular Therapy Program, Salt Lake City, Utah, USA.ORCID https://orcid.org/0000-0001-8961-4639
Joseph UbertiKarmanos Cancer Center, Hudson-Webber Cancer Research Center, Detroit, Michigan, USA.
Guido MarcucciDepartment of Hematologic Malignancies Translational Science, Beckman Research Institute of City of Hope, Monrovia, California, USA.
Jason GotlibDivision of Hematology, Stanford University School of Medicine, Stanford Cancer Institute, Stanford, California, USA.
Cem AkinDivision of Allergy and Clinical Immunology, Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Mehdi HamadaniCIBMTR® (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Milwaukee, Wisconsin, USA.ORCID https://orcid.org/0000-0001-5372-510X
Vinod PullarkatDepartment of Hematologic Malignancies Translational Science, Beckman Research Institute of City of Hope, Monrovia, California, USA.
Peter ValentDivision of Hematology & Hemostaseology, Department of Internal Medicine I, and Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Vienna, Austria.
Michael GrunwaldDepartment of Hematologic Oncology and Blood Disorders, Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, North Carolina, USA.
Mark JuckettDivision of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota, USA.
Betul OranDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0003-1264-5968
Wael SaberCIBMTR® (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Linda J BurnsCIBMTR® (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Milwaukee, Wisconsin, USA.

Funding

Data Resource for Analyzing Blood &Marrow TransplantsU24CA076518 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI Amy M Moskop, Bronwen Shaw · 1998 to 2026
$105.2M
Coleman FoundationNCI NIH HHS U24 CA076518
6 · The paper itself

Abstract

We investigated the outcomes of patients with advanced systemic mastocytosis (AdvSM) undergoing allogeneic haematopoietic cell therapy (alloHCT) in the US. Twenty-seven adult (median age, 58 years) patients with AdvSM received alloHCT from 2014 to 2021. Most patients were white (93%), male (63%) and had systemic mastocytosis (SM) with associated haematological neoplasm (SM-AHN, 70%), received peripheral blood grafts (89%) and non-myeloablative regimens. KIT mutation was detected in 14 of the reported 16 patients (87.5%). Post-transplantation cyclophosphamide (PTCy) was used in approximately 50% of the cohort. Approximately 1 year after alloHCT, median bone marrow mast cell burden decreased from 15% pre-alloHCT to 1.5% (range 0-8) at 1 year post-alloHCT. The median serum tryptase decreased from 55 ng/mL (range 3-400 ng/mL) pre-alloHCT to 18 ng/mL (range 0-481 ng/mL) at 1 year post-alloHCT. At 1 year, progression-free survival (PFS) and overall survival (OS) were 59% (95% confidence interval [CI], 41%-77%) and 74% (95% CI, 56%-89%) respectively. In the subset of patients with SM-AHN, 1-year PFS and OS were 74% (52%-91%) and 79% (95% CI, 58%-94%) respectively. The cumulative incidence of relapse/progression for the entire population of patients with SM (n = 27) was 4% (95% CI, 0-14) at 100 days and 15% (95% CI, 4-31) at 1 year. For the subset of patients with AHN, the cumulative incidence was 11% (95% CI, 1-28) at 100 days and 21% (95% CI, 6-42) at 1 year. Relapse/progression was the cause of death in six of 12 patients (5 died of AHN and 1 died of SM progression). Eighteen and nine patients received a KIT inhibitor before alloHCT and after alloHCT respectively. In addition, six patients received a KIT inhibitor for the treatment of relapse/progression of SM after alloHCT. Although it is difficult to delineate the exact effect of alloHCT and KIT inhibitors because of the size of the study in this era, the use of alloHCT and KIT inhibitors pre- and post- alloHCT is increasing. In the near future, larger studies are required to provide further insights into this subject.

Indexed as

Hematopoietic Stem Cell TransplantationMastocytosis, SystemicAdultAgedCyclophosphamideFemaleHumansMaleMiddle AgedProto-Oncogene Proteins c-kitTransplantation ConditioningTransplantation, HomologousCyclophosphamideProto-Oncogene Proteins c-kitallogeneicbone marrow transplantationmast cellssystemic mastocytosistryptase

Identifiers

PMID40983528
PMCPMC12519450

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.